Latest Breaking News On - Carsgen therapeutics holdings - Page 5 : comparemela.com

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

SHANGHAI, Oct. 18, 2022 /PRNewswire/ CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell th.

CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

/PRNewswire/ CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of.

Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

/PRNewswire/ CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of.

CARsgen Appoints Dr. Hua Jiang as Executive Director

/PRNewswire/ CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of.